دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Positive Prostate-specific Membrane Antigen Findings: How To Interpret Them
Kelsey L. Pomykala a , Ken Herrmann b , Elisabetta Lalumera c , Stefano Fanti
doi : 10.1016/j.euo.2022.10.007
Volume 6, Issue 2, April 2023, Pages 113-115
Magnetic Resonance Imaging–guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis
Darren M.C. Poon a,y,*, Jing Yuan b,y, Bin Yang c , Linda G.W. Kerkmeijer d , Amar U. Kishan e , Vedang Murthy f , Alison Tree g , Almudena Zapatero h , Oi Lei Wong
doi : 10.1016/j.euo.2022.10.001
Volume 6, Issue 2, April 2023, Pages 116-127
It is anticipated that a focal boost to intraprostatic lesions (IPLs) using external beam radiotherapy (EBRT) guided by magnetic resonance imaging (MRI) will increase biochemical disease-free survival (bDFS) without increasing toxicity in the treatment of localized prostate cancer (PC).
Metastatic Sites’ Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review
Francesco Mattana a,y, Lorenzo Muraglia a,y, Pawel Rajwa b,c , Fabio Zattoni d , Giancarlo Marra e , Peter K.F. Chiu f , Isabel Heidegger g , Veeru Kasivisvanathan h , Claudia V. Kesch i,j , Jonathan Olivier k , Felix Preisser l , Constance Thibault m , Massimo Valerio n , Roderick C.N. van den Bergh o , Giorgio Gandaglia p,q,Ã , Francesco Ceci a,r,Ã ,*, on behalf of the European Association of Urology Young Academic Urologists Prostate Cancer Working Party
doi : 10.1016/j.euo.2023.01.014
Volume 6, Issue 2, April 2023, Pages 128-136
The introduction of prostate-specific membrane antigen positron emission tomography (PSMA-PET) had a substantial impact on the management of prostate cancer (PCa) patients with a stage migration phenomenon and consequent treatment changes.
Estimating Postoperative Renal Function After Surgery for Nonmetastatic Renal Masses: A Systematic Review of Available Prediction Models
Alessio Pecoraro a,b,y, Riccardo Campi a,c,y, Riccardo Bertolo d , Maria Carmen Mir e , Michele Marchioni f , Sergio Serni a,c , Steven Joniau b , Hendrik Van Poppel b , Maarten Albersen b , Eduard Roussel
doi : 10.1016/j.euo.2022.11.007
Volume 6, Issue 2, April 2023, Pages 137-147
A variety of models predicting postoperative renal function following surgery for nonmetastatic renal tumors have been reported, but their validity and clinical usefulness have not been formally assessed.
Prediction of Renal Function after Radical and Partial Nephrectomy: An Argument for Conceptual Simplicity
Nityam Rathi a , Worapat Attawettayanon a,b , Carlos Munoz-Lopez a , Steven C. Campbell
doi : 10.1016/j.euo.2023.01.007
Volume 6, Issue 2, April 2023, Pages 148-150
Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial
Shay Golan a,b,*, Michael Frumer a,b , Yarden Zohar a , Eli Rosenbaum b,c , Maxim Yakimov b,d , Daniel Kedar a,b , David Margel a,b , Jack Baniel a,b , Adam P. Steinmetz b,e , David Groshar b,e , Liran Domachevsky b,f , Hanna Bernstine
doi : 10.1016/j.euo.2022.09.002
Volume 6, Issue 2, April 2023, Pages 151-159
High-risk localized prostate cancer (HRLPC) has a substantial risk of disease progression despite local treatment. Neoadjuvant systemic therapy before definitive local therapy may improve oncological outcomes by targeting the primary tumor and micrometastatic disease.
Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting
Caroline M. Moore a,b,*, Lauren E. King c , John Withington a,b , Mahul B. Amin d,e , Mark Andrews f , Erik Briers g , Ronald C. Chen h , Francis I. Chinegwundoh i,j , Matthew R. Cooperberg k,l,m , Jane Crowe n , Antonio Finelli o,p,q , Margaret I. Fitch r , Mark Frydenberg s,t , Francesco Giganti a,u , Masoom A. Haider v,w , John Freeman f , Joseph Gallo x , Stephen Gibbs f , Anthony Henry y , Nicholas James z , Netty Kinsella aa,ab , Thomas B.L. Lam ac,ad , Mark Lichty x , Stacy Loeb ae,af,ag , Brandon A. Mahal ah , Ken Mastris ai , Anita V. Mitra aj , Samuel W.D. Merriel ak,bb , Theodorus van der Kwast al , Mieke Van Hemelrijck aa , Nynikka R. Palmer am,an,ao , Catherine C. Paterson ap,aq , Monique J. Roobol ar , Phillip Segal as , James A. Schraidt at , Camille E. Short au,av , M. Minhaj Siddiqui aw , Clare M.C. Tempany ax,ay , Arnaud Villers az , Howard Wolinsky ba,bc , Steven MacLennan
doi : 10.1016/j.euo.2023.01.003
Volume 6, Issue 2, April 2023, Pages 160-182
Active surveillance (AS) is recommended for low-risk and some intermediate-risk prostate cancer. Uptake and practice of AS vary significantly across different settings, as does the experience of surveillance—from which tests are offered, and to the levels of psychological support.
A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines
Joep J. de Jong a,*, Olga M. Pijpers a , Kim. E.M. van Kessel a , Joost. L. Boormans a , Wim Van Criekinge b , Ellen C. Zwarthoff c , Yair Lotan
doi : 10.1016/j.euo.2022.08.002
Volume 6, Issue 2, April 2023, Pages 183-189
According to the recent American Urological Association (AUA) guideline on hematuria, patients are stratified into groups with low, intermediate, and high risk of urothelial carcinoma (UC). These risk groups are based on clinical factors and do not incorporate urine-based tumor markers.
Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon–degrading Bacteria Among Bladder Cancer Patients
Laura Bukavina a,b,c,*, Ilaha Isali b,c , Rashida Ginwala b , Mohit Sindhani d , Adam Calaway b,c , Diana Magee a , Benjamin Miron a , Andres Correa a , Alexander Kutikov a , Matthew Zibelman a , Mahmoud Ghannoum b,c , Mauricio Retuerto c , Lee Ponsky b,c , Sarah Markt c , Robert Uzzo a , Philip Abbosh
doi : 10.1016/j.euo.2023.02.004
Volume 6, Issue 2, April 2023, Pages 190-203
The application of next-generation sequencing techniques has enabled characterization of urinary tract microbiome. Although many studies have demonstrated associations between the human microbiome and bladder cancer (BC), these have not always reported consistent results, thereby necessitating cross-study comparisons. Thus, the fundamental questions remain how we can utilize this knowledge.
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Chun Loo Gan a,y, Jiaming Huang b,y, Elizabeth Pan c , Wanling Xie b , Andrew L. Schmidt b , Chris Labaki b , Luis Meza d , Gabrielle Bouchard b , Haoran Li e , Francesca Jackson-Spence f , Carla Sa �nchez-Ruiz g , Thomas Powles f , Shruti A. Kumar e , Nicole Weise c , William A. Hall h , Brent S. Rose b , Benoit Beuselinck i , Cristina Suarez g , Sumanta K. Pal d , Toni K. Choueiri b , Daniel Y.C. Heng a , Rana R. McKay
doi : 10.1016/j.euo.2022.10.004
Volume 6, Issue 2, April 2023, Pages 204-211
There is a paucity of data on the safety of cabozantinib use in combination with radiotherapy.
Concurrent Stereotactic Ablative Radiotherapy and Antiangiogenic Targeted Agents: Redefining the Therapeutic Strategy
Mimma Rizzo a , Camillo Porta
doi : 10.1016/j.euo.2022.11.001
Volume 6, Issue 2, April 2023, Pages 212-213
Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum
Irene J. Beijert a,b , Anouk E. Hentschel a,b , Johannes Bru ̈ndl c , Eva M. Compe �rat d,e , Karin Plass f , Oscar Rodrı �guez g , Jose D. Subiela Henrı �quez g , Virginia Herna �ndez d,h , Enrique de la Pen ̃a h , Isabel Alemany i , Diana Turturica j , Francesca Pisano g,j , Francesco Soria j , Otakar Cˇapoun d,k , Lenka Bauerova � l , Michael Pesˇl k , H. Maxim Bruins d,m ,
doi : 10.1016/j.euo.2023.01.004
Volume 6, Issue 2, April 2023, Pages 214-221
Ta grade 3 (G3) non–muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the lower malignant potential of the Ta component.
Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer
Marie-Pier St-Laurent *, Jonathan Suderman, Peter C. Black
doi : 10.1016/j.euo.2023.02.003
Volume 6, Issue 2, April 2023, Pages 222-223
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography
Clayton P. Smith a , James A. Proudfoot b , Paul C. Boutros c,d , Robert E. Reiter d , Luca Valle a , Matthew B. Rettig d,e , Nicholas G. Nickols a , Felix Y. Feng f , Paul L. Nguyen g , Himanshu Nagar h , Daniel E. Spratt i , Gert Attard j , Adam Weiner d , Joanne B. Weidhaas a , Jeremie Calais k , T. Martin Ma a , Elai Davicioni b , Michael Xiang a , Amar U. Kishan
doi : 10.1016/j.euo.2023.02.009
Volume 6, Issue 2, April 2023, Pages 224-227
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has greater specificity and sensitivity for detection of extraprostatic prostate cancer (PCa) at presentation than conventional imaging. Although the long-term clinical significance of acting on these findings is unknown, it has been shown that the risk of upstaging is prognostic for long-term outcomes in men with high-risk (HR) or very high-risk (VHR) PCa.
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
Omar Alhalabi a,y,*, Yueting Zhu a,b,y, Ameer Hamza c , Wei Qiao d , Yiyun Lin e , Raymond M. Wang a , Amishi Y. Shah a , Matthew T. Campbell a , Vijaykumar Holla f , Ashish Kamat g , Wei-Lien Wang c , Jennifer Wang a , Jianfeng Chen a , Jieru Meng a , Miao Zhang c , Jolanta Bondaruk c , Mark Titus a , Giannicola Genovese a , Bogdan A. Czerniak c , Kenna R. Shaw f , Funda Meric-Bernstam h , Charles C. Guo c , Christopher J. Logothetis a , Arlene Siefker-Radtke a , Pavlos Msaouel a,Ã , Linghua Wang h,Ã , Jiyan Liu b,Ã , Jianjun Gao
doi : 10.1016/j.euo.2021.10.006
Volume 6, Issue 2, April 2023, Pages 228-232
Deficiency of MTAP (MTAPdef) mainly occurs because of homozygous loss of chromosome 9p21, which is the most common copy-number loss in metastatic urothelial cancer (mUC).
Re: Yosuke Yasuda, J.J.H. Zhang, Worapat Attawettayanon, et al. Comprehensive Management of Renal Masses in Solitary Kidneys. Eur Urol Oncol. 2023;6:84–94
Kuan-Yu Chen a Sung-Lang Chen a,b Wen-Wei Sung
doi : 10.1016/j.euo.2023.02.001
Volume 6, Issue 2, April 2023, Page 233
Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126–37
Juan Morote
doi : 10.1016/j.euo.2023.02.002
Volume 6, Issue 2, April 2023, Page 234
Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126–37
Louis Lenfant * Pierre Mozer Thomas Seisen
doi : 10.1016/j.euo.2023.01.005
Volume 6, Issue 2, April 2023, Page 235
